StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report report published on Monday morning. The firm issued a sell rating on the stock.

Several other research analysts have also recently weighed in on the company. D. Boral Capital restated a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research note on Tuesday, December 10th. Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Stock Up 2.2 %

Shares of VNRX opened at $0.63 on Monday. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23. The company has a market capitalization of $58.27 million, a P/E ratio of -1.75 and a beta of 1.17. The firm has a 50 day moving average of $0.66 and a 200 day moving average of $0.66.

Insider Buying and Selling

In other VolitionRx news, CEO Cameron John Reynolds acquired 139,811 shares of the company’s stock in a transaction that occurred on Monday, December 9th. The shares were bought at an average price of $0.57 per share, with a total value of $79,692.27. Following the completion of the acquisition, the chief executive officer now owns 2,117,404 shares in the company, valued at $1,206,920.28. This represents a 7.07 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Guy Archibald Innes bought 174,764 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were acquired at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the transaction, the director now directly owns 617,085 shares of the company’s stock, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 358,266 shares of company stock worth $204,212. 12.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in VolitionRx stock. Geode Capital Management LLC increased its position in VolitionRx Limited (NYSE:VNRX) by 15.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 730,448 shares of the company’s stock after acquiring an additional 95,900 shares during the quarter. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.